KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Capital Expenditures (2016 - 2025)

Eli Lilly (LLY) has disclosed Capital Expenditures for 17 consecutive years, with $2.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 70.21% year-over-year to $2.5 billion, compared with a TTM value of $7.8 billion through Dec 2025, up 55.02%, and an annual FY2025 reading of $7.8 billion, up 55.02% over the prior year.
  • Capital Expenditures was $2.5 billion for Q4 2025 at Eli Lilly, up from $2.1 billion in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.5 billion in Q4 2025 and bottomed at $291.4 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $975.6 million, with a median of $854.2 million recorded in 2023.
  • The sharpest move saw Capital Expenditures crashed 35.91% in 2021, then skyrocketed 113.9% in 2023.
  • Year by year, Capital Expenditures stood at $291.4 million in 2021, then soared by 71.83% to $500.7 million in 2022, then surged by 113.9% to $1.1 billion in 2023, then skyrocketed by 39.7% to $1.5 billion in 2024, then soared by 70.21% to $2.5 billion in 2025.
  • Business Quant data shows Capital Expenditures for LLY at $2.5 billion in Q4 2025, $2.1 billion in Q3 2025, and $1.7 billion in Q2 2025.